Atopic Dermatitis (Eczema) clinical trials at UCSF

• Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

  open to eligible people ages 18 years and up

  This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.

  San Francisco, California

• Systemic Therapies for Pediatric Atopic Dermatitis

  open to eligible people ages 2-17

  While many patients with atopic dermatitis (eczema) can be managed with topical creams and treatments for itch, some children have such severe, long-standing disease that they need treatment with oral medications that decrease the ability of the immune system to react. However, there is not enough information on the proper use of these medications or how well they work compared with each other. The current study looks at the response of children treated with these medications to provide this information and improve their use.

  San Francisco, California and other locations

• The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

  open to eligible people ages 18 years and up

  This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.

  San Francisco, California

• Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

  Sorry, not currently recruiting here

  Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

  San Francisco, California and other locations

• Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis

  Sorry, in progress, not accepting new patients

  This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.

  Fresno, California and other locations

• Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use

  Sorry, not yet accepting patients

  Design and beta-test a research-oriented mobile health app to assess disease activity, quality of life, treatment patterns, adverse medication effects, and lifestyle factors in patients with atopic dermatitis.

  San Francisco, California

Last updated: February 8, 2021